The publisher explores Bayer’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (26 April 2020)
Model updates (26 February 2020)
Model updates (30 October 2019)
Model updates (9 August 2019)
Snapshot
- Overview: Bayer’s prescription drug sales will experience modest growth over the forecast period.
- Key themes: [1] Xarelto and Eylea, Bayer’s two flagship drugs, will see robust global growth in the short term [2] Growth in China is key for several of Bayer’s franchises [3] Genitourinary remains a key therapy area, as Mirena will drive sales growth.
Model updates (26 April 2020)
- Xarelto forecast adjusted higher due to higher volumes globally and stable performance in the US
- Glucobay forecast adjusted lower due to COVID-19 impact in China
- Jivi forecast removed due to Bayer consolidating Jivi sales with Kogenate.
Model updates (26 February 2020)
- Eylea forecast adjusted higher due to continued strength in Europe, Japan, and the Middle East
- Betaferon/Betaseron forecast adjusted lower due to continued market share losses in the US.
Model updates (30 October 2019)
- Eylea forecast adjusted higher due to continued strength in Europe, Japan, and Middle East
- Yaz/Yasmin/Yasminelle forecast adjusted higher
- Betaferon/Betaseron forecast adjusted lower due to continued market share losses in US.
Model updates (9 August 2019)
- Xarelto forecast adjusted lower in the US due to lower licensing revenues from Johnson & Johnson, and higher in Europe and RoW, driven by expanded volumes in China, Russia, and France
- Eylea forecast adjusted higher due to strength in Europe, Japan, and Canada
- Nexavar sales adjusted higher in China and lower in the US and Japan
- Stivarga forecast adjusted higher due to expanded volumes in China and Russia
- Aliqopa forecast adjusted lower due to 5EU and RoW launches being pushed out
- Vericiguat forecast added
- Nubeqa forecast added
- Molidustat forecast added
- Finerenone forecast added
- Vericiguat forecast added
- Other revenue adjusted lower due to sale of Animal Health division to Elanco.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
